Skip to main content
SpringerLink
Log in

Iron, a new aid in the treatment of Parkinson patients

  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

One of the problems in treating Parkinson patients is the so called “off-effect” which occurs after long term treatment with L-DOPA. Off-effects are characterized by severe rigor and akinesia. Increasing dosages of L-DOPA and decarboxylase- or monoaminooxidase-inhibitors do not improve these symptoms. Intravenously applied iron-in form of a ferri-ferro-complex-exhibited a considerable benefit for all patients treated so far. They regained a remarkable mobility. Their disability score dropped from up to 90% down to 30%. The effect of iron is dosage-dependent and lasts 24 to 48 hours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanin (L-DOPA)-Effekt bei der Parkinson-Akinesie. Wien Klin Wochenschr 73: 787

    Google Scholar 

  • Birkmayer W (1969) Experimentelle Ergebnisse über die Kombinations-behandlung des Parkinson-Syndroms mit L-DOPA und einem Decarbo-xylasehemmer. Wien Klin Wochenschr 81: 677

    Google Scholar 

  • Birkmayer W, Neumayer E (1972) Die moderne medikamentöse Behandlung des Parkinsonismus. Z Neurol 202: 257

    Google Scholar 

  • Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, Deprenyl. J Neural Transm 36: 303

    Google Scholar 

  • Birkmayer W, Riederer P (1985) Die Parkinson-Krankheit, 2. Aufl. Springer, Wien New York

    Google Scholar 

  • Carlsson A, Lindquist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine ad 5-hydroxytryptophan as reserpine antagonists. Nature 180: 1200

    Google Scholar 

  • Carlsson A, Lindquist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 137: 471

    Google Scholar 

  • Nagatsu T, Namaguchi T, Kato T, Sugimoto T, Matsuura S, Akino M, Nagatsu I, Iizuka R, Narabayashi H (1981) Biopterin in human brain and urine from controls and parkinsonian patients: application of a new radioimmuno assay. Clin Chim Acta 109: 305–311

    Google Scholar 

  • Riederer P, Sofic E, Rausch WD, Kruzik P, Youdim MBH (1985) Dopamin-forschung heute und morgen—L-DOPA in der Zukunft. In: Riederer P, Umek H (eds) L-Dopa-Substitution der Parkinson-Krankheit. Springer, Wien New York, pp 127–140

    Google Scholar 

Download references

Author information

Author notes

  1. W. Birkmayer

    Present address: Evangelic Hospital, Wien, Austria

Authors and Affiliations

  1. Department of Medical Chemistry, University of Graz, Austria

    J. G. D. Birkmayer

Authors
  1. W. Birkmayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. G. D. Birkmayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Birkmayer, W., Birkmayer, J.G.D. Iron, a new aid in the treatment of Parkinson patients. J. Neural Transmission 67, 287–292 (1986). https://doi.org/10.1007/BF01243354

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01243354

Key words

Search

Navigation